Straube, Sebastian

[["dc.bibliographiccitation.firstpage","318"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Geburtshilfe und Frauenheilkunde"],["dc.bibliographiccitation.lastpage","323"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Voigt, M."],["dc.contributor.author","Schild, R. L."],["dc.contributor.author","Mewitz, M."],["dc.contributor.author","Schneider, K. T. M."],["dc.contributor.author","Schnabel, Dirk"],["dc.contributor.author","Hesse, Volker"],["dc.contributor.author","Straube, Sebastian"],["dc.date.accessioned","2018-11-07T09:26:17Z"],["dc.date.available","2018-11-07T09:26:17Z"],["dc.date.issued","2013"],["dc.description.abstract","Background and Aim: The classification of weight gain during pregnancy and the somatic classification of neonates according to birth weight and duration of pregnancy can be done using percentile values. We aimed to compare such classifications using percentiles of the overall study population with classifications using percentiles that were calculated taking account of maternal height and weight. Material and Methods: Using data from the German Perinatal Survey (1995-2000, over 2.2 million singleton pregnancies) we classified weight gain during pregnancy as low (< 10th percentile), high (> 90th percentile), or medium (10th-90th percentile). Neonates were classified by birth weight as small for gestational age (SGA, < 10th percentile), large for gestational age (LGA, > 90th percentile), or appropriate for gestational age (AGA, 10th-90th percentile). Classifications were performed for 12 groups of women and their neonates formed according to maternal height and weight, either with the percentiles calculated from the total study population or with group-specific percentiles. Results: Using percentiles of the total study population there was large variability between the 12 groups in the proportions with low and high weight gain and in the proportions of SGA and LGA neonates. The variability was much lower when group-specific percentiles were used. Conclusions: Classifications of maternal weight gain during pregnancy and birth weight differ substantially, depending on whether percentiles calculated from the total study population or group-specific percentiles are used. The impact of using percentiles that take account of maternal anthropometric parameters for the medical care and health of neonates needs to be elucidated in future research."],["dc.identifier.doi","10.1055/s-0032-1328436"],["dc.identifier.isi","000318908700009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30267"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1438-8804"],["dc.relation.issn","0016-5751"],["dc.title","Maternal Weight Gain during Pregnancy and Somatic Classification of Neonates According to Birth Weight and Duration of Pregnancy Taking Account of Maternal Body Weight and Height"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","425"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Perinatal Medicine"],["dc.bibliographiccitation.lastpage","430"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Voigt, Manfred"],["dc.contributor.author","Rochow, Niels"],["dc.contributor.author","Jaehrig, Klaus"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Hufnagel, Sven"],["dc.contributor.author","Jorch, Gerhard"],["dc.date.accessioned","2018-11-07T08:41:50Z"],["dc.date.available","2018-11-07T08:41:50Z"],["dc.date.issued","2010"],["dc.description.abstract","Neonatal anthropometric data reflect intrauterine development and correlate with postnatal outcome. Therefore, classification of neonates by body dimensions, using gestational age-adjusted population percentiles, is clinically practiced. However, neonatal anthropometric variables are also influenced by maternal constitution and the extent of this influence is currently unknown. We analyzed small for gestational age (SGA) and large for gestational age (LGA) rates according to maternal height and weight. We used data of about 2.3 million singleton pregnancies from the German Perinatal Survey of 1995-2000. A close correlation between maternal and neonatal anthropometric data was found; SGA rates were inversely proportional and LGA rates were directly proportional to maternal height, weight, and body mass index. Neonates of small and light mothers (<155 cm, <50 kg) had, according to the presently used classification scheme, an SGA rate of 25.3% and an LGA rate of 1.7%, respectively. Newborns to tall and heavy women (>179 cm, 89 kg) had a much lower SGA rate (3.1%) and a much higher LGA rate (30.6%). Neonatal body length and head circumference depended on maternal stature in a similar way. Some neonates who are \"appropriate'' for their gestational age in that they achieve their genetically determined growth potential are therefore apparently misclassified as SGA or LGA."],["dc.identifier.doi","10.1515/JPM.2010.059"],["dc.identifier.isi","000279520400012"],["dc.identifier.pmid","20443667"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19556"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Walter De Gruyter & Co"],["dc.relation.issn","0300-5577"],["dc.title","Dependence of neonatal small and large for gestational age rates on maternal height and weight - an analysis of the German Perinatal Survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0137052"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Roever, Christian"],["dc.contributor.author","Nicholas, Richard"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Friede, Tim"],["dc.date.accessioned","2018-11-07T09:52:42Z"],["dc.date.available","2018-11-07T09:52:42Z"],["dc.date.issued","2015"],["dc.description.abstract","Background Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS) revealed a decrease in placebo annualized relapse rates (ARR) over the past two decades. Furthermore, regression to the mean effects were observed in ARR and MRI lesion counts. It is unclear whether disease progression measured by the expanded disability status scale (EDSS) exhibits similar features. Methods A systematic review of RCTs in RMS was conducted extracting data on EDSS and baseline characteristics. The logarithmic odds of disease progression were modelled to investigate time trends. Random-effects models were used to account for between-study variability; all investigated models included trial duration as a predictor to correct for unequal study durations. Meta-regressions were conducted to assess the prognostic value of a number of study-level baseline variables. Results The systematic literature search identified 39 studies, including a total of 19,714 patients. The proportion of patients in placebo controls experiencing a disease progression decreased over the years (p<0.001). Meta-regression identified associated covariates including the size of the study and its duration that in part explained the time trend. Progression probabilities tended to be lower in the second year of a study compared to the first year with a reduction of 28% in progression odds from year 1 to year 2 (p = 0.017). Conclusion EDSS disease progression exhibits similar behaviour over time as the ARR and point to changes in trial characteristics over the years. This needs to be considered in comparisons between historical and recent trials."],["dc.description.sponsorship","NIHR Biomedical Research Centre"],["dc.identifier.doi","10.1371/journal.pone.0137052"],["dc.identifier.isi","000360437700086"],["dc.identifier.pmid","26327532"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12070"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36182"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD008183"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:23Z"],["dc.date.available","2018-11-07T08:47:23Z"],["dc.date.issued","2010"],["dc.description.abstract","Background Gabapentin is an antiepileptic drug, also used in the treatment of neuropathic pain, which is the subject of a Cochrane review, currently under revision. Its efficacy in treating established acute postoperative pain has not been demonstrated. Objectives To assess the efficacy and safety of single dose oral gabapentin compared with placebo in established acute postoperative pain using methods that permit comparison with other analgesics. Search strategy We searched Cochrane CENTRAL, MEDLINE, EMBASE, and the Oxford Pain Relief Database. Additional studies were sought from reference lists of retrieved articles and reviews. Clinical trials databases were searched for unpublished studies; clinical trial reports of several unpublished studies have been made public following litigation in the US. Selection criteria Single oral dose, randomised, double-blind, placebo-controlled trials of gabapentin for relief of established moderate to severe postoperative pain in adults. Data collection and analysis Studies were assessed for methodological quality and data extracted by two review authors independently. Numbers of participants with at least 50% of maximum possible total pain relief (TOTPAR) or summed pain intensity difference (SPID) with gabapentin or placebo were calculated and used to derive relative benefit (RB) or risk (RR), and number-needed-to-treat-to-benefit (NNT). Numbers of participants using rescue medication, and time to its use, were sought as additional measures of efficacy. Information on adverse events and withdrawals was collected. Main results Four unpublished studies met inclusion criteria; in three, participants had pain following dental surgery, and one followed major orthopaedic surgery; 177 participants were treated with a single dose of gabapentin 250 mg, 21 with gabapentin 500 mg, and 172 with placebo. At least 50% pain relief over 6 hours was achieved by 15% with gabapentin 250 mg and 5% with placebo; giving a RB of 2.5 (95% CI 1.2 to 5.0) and an NNT of 11 (6.4 to 35). Significantly fewer participants needed rescue medication within 6 hours with gabapentin 250 mg than with placebo; NNT to prevent use 5.8. About one third of participants reported adverse events with both gabapentin 250 mg and placebo. No serious adverse events occurred with gabapentin. Authors' conclusions Gabapentin 250 mg is statistically superior to placebo in the treatment of established acute postoperative pain, but the NNT of 11 for at least 50% pain relief over 6 hours with gabapentin 250 mg is of limited clinical value and inferior to commonly used analgesics. Gabapentin 250 mg is not clinically useful as a stand-alone analgesic in established acute postoperative pain, though this is probably the first demonstration of analgesic effect of an antiepileptic in established acute pain."],["dc.description.sponsorship","NHS; NIHR; Oxford Pain Research Funds"],["dc.identifier.doi","10.1002/14651858.CD008183.pub2"],["dc.identifier.isi","000277611100029"],["dc.identifier.pmid","20464764"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20937"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Single dose oral gabapentin for established acute postoperative pain in adults"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","161"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Zeitschrift für Geburtshilfe und Neonatologie"],["dc.bibliographiccitation.lastpage","166"],["dc.bibliographiccitation.volume","214"],["dc.contributor.author","Voigt, M."],["dc.contributor.author","Briese, Volker"],["dc.contributor.author","Carstensen, M."],["dc.contributor.author","Wolterdorf, F."],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","Straube, Sebastian"],["dc.date.accessioned","2018-11-07T08:41:15Z"],["dc.date.available","2018-11-07T08:41:15Z"],["dc.date.issued","2010"],["dc.description.abstract","Aim: A description of preterm birth rates - specified according to maternal age - after the exclusion of anamnestic risk factors. Material and Methods: Data for this study were taken from the German Perinatal Survey of 1998-2000. We analysed data from 492 576 single ton pregnancies and determined preterm birth rates according to maternal age after a stepwise exclusion of anamnestic risk factors. Results: There was a U-shaped dependence of preterm birth rates on maternal age. The low est preterm birth rate (without excluding women with anamnestic risk factors) was 5.6 % at a maternal age of 29 years. The prevalence of some anamnestic risk factors for preterm birth, such as previous stillbirths, spontaneous and induced abortions, and ectopic pregnancies, increased with maternal age. Excluding women with anam nestic risk factors lowered the preterm birth rates substantially. The lowest preterm birth rates were found in women with one previous live birth, without any anamnestic risk factors, and with a body mass index (BMI) of 25.00-29.99. With these restrictions, we found preterm birth rates of under 2 % for women aged 24-31 years. Conclusions: The magnitude and age-dependence of the preterm birth rate can to some extent be explained with the age-dependent prevalence of anamnestic risk factors for preterm birth. Excluding women with anamnestic risk factors from our study population lowered the preterm birth rates substantially."],["dc.identifier.doi","10.1055/s-0030-1254140"],["dc.identifier.isi","000208514200005"],["dc.identifier.pmid","20806151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0948-2393"],["dc.title","Age-Specific Preterm Birth Rates after Exclusion of Risk Factors - An Analysis of the German Perinatal Survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD007771"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:24Z"],["dc.date.available","2018-11-07T08:47:24Z"],["dc.date.issued","2010"],["dc.description.abstract","Background Vitamin D is produced in the skin after sun-light exposure and can also be obtained through food. Vitamin D deficiency has recently been linked with a range of diseases including chronic pain. Observational and circumstantial evidence suggests that there may be a role for vitamin D deficiency in the aetiology of chronic pain conditions. Objectives To assess the efficacy and adverse events of vitamin D supplementation in chronic painful conditions. Search strategy We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies to September 2009. This was supplemented by searching the reference lists of retrieved articles, textbooks and reviews. Selection criteria Studies were included if they were randomised double blind trials of vitamin D supplementation compared with placebo or with active comparators for the treatment of chronic pain conditions in adults. Data collection and analysis Two review authors independently selected the studies for inclusion, assessed methodological quality, and extracted data. Pooled analysis was not undertaken due to paucity and heterogeneity of data. Main results Four studies, with a total of 294 participants, were included. The studies were heterogeneous with regard to study quality, the chronic painful conditions that were investigated, and the outcome measures reported. Only one study reported a beneficial effect, the others found no benefit of vitamin D over placebo in treating chronic pain. Authors' conclusions The evidence base for the use of vitamin D for chronic pain in adults is poor at present. This is due to low quality and insufficient randomised controlled trials in this area of research."],["dc.description.sponsorship","NHS Cochrane Collaboration UK; NIHR"],["dc.identifier.doi","10.1002/14651858.CD007771.pub2"],["dc.identifier.isi","000274653900040"],["dc.identifier.pmid","20091647"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20938"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Vitamin D for the treatment of chronic painful conditions in adults"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1580"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","1586"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Steinvorth, Simon M."],["dc.contributor.author","Roever, Christian"],["dc.contributor.author","Schneider, Simon"],["dc.contributor.author","Nicholas, Richard"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Friede, Tim"],["dc.date.accessioned","2018-11-07T09:19:24Z"],["dc.date.available","2018-11-07T09:19:24Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS). Methods: We conducted a systematic literature search of RCTs in RMS. Data on eligibility criteria and baseline characteristics were extracted and tested for significant trends over time. A meta-regression was conducted to estimate their contribution to the decrease of trial ARRs over time. Results: We identified 56 studies. Patient age at baseline (p < 0.001), mean duration of multiple sclerosis (MS) at baseline (p = 0.048), size of treatment groups (p = 0.003), Oxford Quality Scale scores (p = 0.021), and the number of eligibility criteria (p<0.001) increased significantly, whereas pre-trial ARR (p = 0.001), the time span over which pre-trial ARR was calculated (p < 0.001), and the duration of placebo-controlled follow-up (p = 0.006) decreased significantly over time. In meta-regression of trial placebo ARR, the temporal trend was found to be insignificant, with major factors explaining the variation: pre-trial ARR, the number of years used to calculate pre-trial ARR and study duration. Conclusion: The observed decline in trial ARRs may result from decreasing pre-trial ARRs and a shorter time period over which pre-trial ARRs were calculated. Increasing patient age and duration of illness may also contribute."],["dc.description.sponsorship","National Institute of Health Research (NIHR) Biomedical Research Centre"],["dc.identifier.doi","10.1177/1352458513481009"],["dc.identifier.isi","000325696100007"],["dc.identifier.pmid","23471144"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10011"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28627"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/13071 gut duplicate"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","386"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","389"],["dc.bibliographiccitation.volume","150"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Eccleston, Christopher"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Bell, Rae F."],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:40:04Z"],["dc.date.available","2018-11-07T08:40:04Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1016/j.pain.2010.05.011"],["dc.identifier.isi","000281675000008"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19142"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","150"],["dc.bibliographiccitation.journal","BMC Musculoskeletal Disorders"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Paine, Jocelyn"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:41:25Z"],["dc.date.available","2018-11-07T08:41:25Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but needs validating for level of response and treatment duration. A consensus group has defined what constitutes minimal, moderate, and substantial benefit based on pain intensity and Patient Global Impression of Change scores. Methods: We obtained individual patient data from four randomised double blind trials of pregabalin in fibromyalgia lasting eight to 14 weeks. We calculated response for all efficacy outcomes using any improvement (>= 0%), minimal improvement (>= 15%), moderate improvement (>= 30%), substantial improvement (>= 50%), and extensive improvement (>= 70%), with numbers needed to treat (NNT) for pregabalin 300 mg, 450 mg, and 600 mg daily compared with placebo. Results: Information from 2,757 patients was available. Pain intensity and sleep interference showed reductions with increasing level of response, a significant difference between pregabalin and placebo, and a trend towards lower (better) NNTs at higher doses. Maximum response rates occurred at 4-6 weeks for higher levels of response, and were constant thereafter. NNTs (with 95% confidence intervals) for >= 50% improvement in pain intensity compared with placebo after 12 weeks were 22 (11 to 870) for pregabalin 300 mg, 16 (9.3 to 59) for pregabalin 450 mg, and 13 (8.1 to 31) for pregabalin 600 mg daily. NNTs for >= 50% improvement in sleep interference compared with placebo after 12 weeks were 13 (8.2 to 30) for pregabalin 300 mg, 8.4 (6.0 to 14) for pregabalin 450 mg, and 8.4 (6.1 to 14) for pregabalin 600 mg. Other outcomes had fewer respondents at higher response levels, but generally did not discriminate between pregabalin and placebo, or show any dose response. Shorter duration and use of 'any improvement' over-estimated treatment effect compared with longer duration and higher levels of response. Conclusions: Responder analysis is useful in fibromyalgia, particularly for pain and sleep outcomes. Some fibromyalgia patients treated with pregabalin experience a moderate or substantial pain response that is consistent over time. Short trials using 'any improvement' as an outcome overestimate treatment effects."],["dc.description.sponsorship","Pfizer Inc.; Oxford Pain Relief Trust; NIHR Biomedical Research Centre"],["dc.identifier.doi","10.1186/1471-2474-11-150"],["dc.identifier.isi","000280833800005"],["dc.identifier.pmid","20602781"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5670"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19464"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2474"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Pregabalin in fibromyalgia - responder analysis from individual patient data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","229"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Zeitschrift für Geburtshilfe und Neonatologie"],["dc.bibliographiccitation.lastpage","233"],["dc.bibliographiccitation.volume","214"],["dc.contributor.author","Voigt, M."],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Gulashvili, A."],["dc.contributor.author","Schild, R. L."],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","Briese, Volker"],["dc.date.accessioned","2018-11-07T08:36:36Z"],["dc.date.available","2018-11-07T08:36:36Z"],["dc.date.issued","2010"],["dc.description.abstract","Aim: The aim of this study was to compare neonatal outcomes in primiparous women with and without previous extrauterine pregnancies. Material and Methods: We analysed data from 207 171 singleton pregnancies in primiparous women from the German Perinatal Survey of 1998-2000. To minimise confounding factors, we only included women without previous miscarriages or terminations of pregnancy and performed comparisons separately for 3 maternal age groups as well as for all cases together. Results: Women with and without previous extrauterine pregnancies were of comparable height and weight but women with previous extrauterine pregnancies were on average older (29.2 vs. 26.6 years). The preterm birth rate was higher in women with previous extrauterine pregnancies (9.4 % vs. 6.8 %, odds ratio 1.42 [95 % confidence interval 1.18-1.69], p < 0.001; analysing all cases together) as was the rate of neonates with a low birth weight <= 2 499 g (7.9 % vs. 5.7 %, odds ratio 1.43 [95 % confidence interval 1.17-1.72], p > 0.001; analysing all cases together). The proportions of neonates classified as small, appropriate, or large for gestational age were rather similar in women with and without previous extrauterine pregnancies; likewise Apgar scores differed only slightly, although for some comparisons statistical significance was reached in spite of the small magnitude of differences. Conclusions: Previous extrauterine pregnancies are associated with higher rates of preterm birth and infants of low birth weight in subsequent pregnancies."],["dc.identifier.doi","10.1055/s-0030-1255026"],["dc.identifier.isi","000208514500002"],["dc.identifier.pmid","21207322"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18352"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0948-2393"],["dc.title","Previous Extrauterine Pregnancies and Neonatal Outcomes in Primiparous Women - An Analysis of the German Perinatal Survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]